Pulmonx (LUNG) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$1.84
+1.7% on the day
+6.4% over 12 months
52-week range $1.17 – $2.60
Share price and insider trades
LUNG closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$548K
Insiders buying0
Insiders selling5
Pulmonx insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 5 sold $548K of LUNG stock on the open market.
Get emailed when insiders cluster-buy stocks like LUNG
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
LUNG insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $177K | 14 |
| Q2 2026 | — | 0 | $144K | 15 |
| Q1 2026 | — | 0 | $141K | 15 |
| Q4 2025 | — | 0 | $86K | 11 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.5×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Pulmonx Corp insiders reported open-market purchases totaling $0, while 5 insiders reported sales totaling $548K. 1 of 55 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 3SEC | Glendon E. French IIICEO, President | Sell | 37,7841,137,936 held (−3%) | $2.26 | $85K | -18.6% | — |
| Sep 3SEC | Srikanth RadhakrishnanChief Science & Techn. Officer | Sell | 5,863316,994 held (−2%) | $2.26 | $13K | -18.6% | — |
| Sep 3SEC | David Aaron LehmanGeneral Counsel | Sell | 4,827361,827 held (−1%) | $2.26 | $11K | -18.6% | — |
| Sep 3SEC | Glendon E. French IIICEO, President | Sell | 4,0981,175,720 held (−0%) | $2.26 | $9K | -18.6% | — |
| Sep 3SEC | David Aaron LehmanGeneral Counsel | Sell | 3,807372,354 held (−1%) | $2.26 | $9K | -18.6% | — |
| Sep 3SEC | Srikanth RadhakrishnanChief Science & Techn. Officer | Sell | 3,618322,857 held (−1%) | $2.26 | $8K | -18.6% | — |
| Sep 3SEC | David Aaron LehmanGeneral Counsel | Sell | 3,476366,654 held (−1%) | $2.26 | $8K | -18.6% | — |
| Sep 3SEC | Srikanth RadhakrishnanChief Science & Techn. Officer | Sell | 2,643328,596 held (−1%) | $2.26 | $6K | -18.6% | — |
| Sep 3SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 2,390453,108 held (−1%) | $2.26 | $5K | -18.6% | — |
| Sep 3SEC | David Aaron LehmanGeneral Counsel | Sell | 2,224370,130 held (−1%) | $2.26 | $5K | -18.6% | — |
| Sep 3SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 2,213455,498 held (−0%) | $2.26 | $5K | -18.6% | — |
| Sep 3SEC | Srikanth RadhakrishnanChief Science & Techn. Officer | Sell | 2,121326,475 held (−1%) | $2.26 | $5K | -18.6% | — |
| Sep 3SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 1,746449,832 held (−0%) | $2.26 | $4K | -18.6% | — |
| Sep 3SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 1,530451,578 held (−0%) | $2.26 | $3K | -18.6% | — |
| Jun 3SEC | Glendon E. French IIICEO, President | Sell | 38,4671,191,673 held (−3%) | $1.54 | $59K | +19.5% | — |
| Jun 3SEC | Glendon E. French IIICEO, President | Sell | 13,5111,178,162 held (−1%) | $1.57 | $21K | +17.2% | — |
| Jun 3SEC | Srikanth RadhakrishnanChief Science &Techn. Officer | Sell | 5,969331,239 held (−2%) | $1.54 | $9K | +19.5% | — |
| Jun 3SEC | David Aaron LehmanGeneral Counsel | Sell | 4,915376,161 held (−1%) | $1.54 | $8K | +19.5% | — |
| Jun 3SEC | Glendon E. French IIICEO, President | Sell | 4,1711,230,140 held (−0%) | $1.54 | $6K | +19.5% | — |
| Jun 3SEC | David Aaron LehmanGeneral Counsel | Sell | 3,876386,879 held (−1%) | $1.54 | $6K | +19.5% | — |
| Jun 3SEC | Srikanth RadhakrishnanChief Science &Techn. Officer | Sell | 3,684337,208 held (−1%) | $1.54 | $6K | +19.5% | — |
| Jun 3SEC | David Aaron LehmanGeneral Counsel | Sell | 3,539381,076 held (−1%) | $1.54 | $5K | +19.5% | — |
| Jun 3SEC | Srikanth RadhakrishnanChief Science &Techn. Officer | Sell | 2,691343,045 held (−1%) | $1.54 | $4K | +19.5% | — |
| Jun 3SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 2,434459,965 held (−1%) | $1.54 | $4K | +19.5% | — |
| Jun 3SEC | David Aaron LehmanGeneral Counsel | Sell | 2,264384,615 held (−1%) | $1.54 | $3K | +19.5% | — |
| Jun 3SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 2,254457,711 held (−0%) | $1.54 | $3K | +19.5% | — |
| Jun 3SEC | Srikanth RadhakrishnanChief Science &Techn. Officer | Sell | 2,153340,892 held (−1%) | $1.54 | $3K | +19.5% | — |
| Jun 3SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 1,778463,956 held (−0%) | $1.54 | $3K | +19.5% | — |
| Jun 3SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 1,557462,399 held (−0%) | $1.54 | $2K | +19.5% | — |
| Mar 4SEC | Glendon E. French IIICEO, President | Sell | 58,3681,409,511 held (−4%) | $1.43 | $83K | +28.7% | — |
| Mar 4SEC | Glendon E. French IIICEO, President | Sell | 6,7371,467,879 held (−0%) | $1.43 | $10K | +28.7% | — |
| Mar 4SEC | David Aaron LehmanGeneral Counsel | Sell | 4,433247,396 held (−2%) | $1.43 | $6K | +28.7% | — |
| Mar 4SEC | Srikanth RadhakrishnanChief Science &Techn. Officer | Sell | 4,198170,736 held (−2%) | $1.43 | $6K | +28.7% | — |
| Mar 4SEC | David Aaron LehmanGeneral Counsel | Sell | 4,051240,755 held (−2%) | $1.43 | $6K | +28.7% | — |
| Mar 4SEC | Srikanth RadhakrishnanChief Science &Techn. Officer | Sell | 3,068177,395 held (−2%) | $1.43 | $4K | +28.7% | — |
| Mar 4SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 2,911365,734 held (−1%) | $1.43 | $4K | +28.7% | — |
| Mar 4SEC | Glendon E. French IIICEO, President | Sell | 2,7081,474,616 held (−0%) | $1.43 | $4K | +28.7% | — |
| Mar 4SEC | David Aaron LehmanGeneral Counsel | Sell | 2,590244,806 held (−1%) | $1.43 | $4K | +28.7% | — |
| Mar 4SEC | Srikanth RadhakrishnanChief Science &Techn. Officer | Sell | 2,461174,934 held (−1%) | $1.43 | $4K | +28.7% | — |
| Mar 4SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 2,125370,506 held (−1%) | $1.43 | $3K | +28.7% | — |
| Mar 4SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 1,861368,645 held (−1%) | $1.43 | $3K | +28.7% | — |
| Mar 4SEC | David Aaron LehmanGeneral Counsel | Sell | 1,163251,829 held (−0%) | $1.43 | $2K | +28.7% | — |
| Mar 4SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 835372,631 held (−0%) | $1.43 | $1K | +28.7% | — |
| Mar 4SEC | Srikanth RadhakrishnanChief Science &Techn. Officer | Sell | 756180,463 held (−0%) | $1.43 | $1K | +28.7% | — |
| Dec 9SEC | Daniel P FlorinDirector | Sell Plan | 23,32193,910 held (−20%) | $1.99 | $46K | -7.5% | — |
| Dec 3SEC | Glendon E. French IIICEO, President | Sell | 6,281277,324 held (−2%) | $1.57 | $10K | +17.2% | — |
| Dec 3SEC | David Aaron LehmanGeneral Counsel | Sell | 3,725258,569 held (−1%) | $1.57 | $6K | +17.2% | — |
| Dec 3SEC | David Aaron LehmanGeneral Counsel | Sell | 3,401252,992 held (−1%) | $1.57 | $5K | +17.2% | — |
| Dec 3SEC | Glendon E. French IIICEO, President | Sell | 2,524283,605 held (−1%) | $1.57 | $4K | +17.2% | — |
| Dec 3SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 2,379373,466 held (−1%) | $1.57 | $4K | +17.2% | — |
| Dec 3SEC | David Aaron LehmanGeneral Counsel | Sell | 2,176256,393 held (−1%) | $1.57 | $3K | +17.2% | — |
| Dec 3SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 1,738377,367 held (−0%) | $1.57 | $3K | +17.2% | — |
| Dec 3SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 1,522375,845 held (−0%) | $1.57 | $2K | +17.2% | — |
| Dec 3SEC | David Aaron LehmanGeneral Counsel | Sell | 976262,294 held (−0%) | $1.57 | $2K | +17.2% | — |
| Dec 3SEC | Geoffrey Beran RoseChief Commercial Officer | Sell | 683379,105 held (−0%) | $1.57 | $1K | +17.2% | — |
Insiders at Pulmonx Corp
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Glendon E. French IIICEO, President | — | $292K | Sep 3, 2026 | — |
| David Aaron LehmanGeneral Counsel | — | $89K | Sep 3, 2026 | — |
| Srikanth RadhakrishnanChief Science & Techn. Officer | — | $70K | Sep 3, 2026 | — |
| Geoffrey Beran RoseChief Commercial Officer | — | $51K | Sep 3, 2026 | — |
| Daniel P FlorinDirector | — | $46K | Dec 9, 2025 | — |
LUNG stock: common questions
Are Pulmonx Corp insiders buying LUNG stock?
In the past 12 months, 0 insiders reported open-market purchases of LUNG worth $0.
Are Pulmonx Corp insiders selling LUNG stock?
5 insiders reported sales worth $548K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is LUNG's 52-week range?
Over the past year LUNG has traded between $1.17 and $2.60. It last closed at $1.84 on Oct 9, 2026.